Affibody Issues New Shares of SEK 200 Million

BROMMA, SWEDEN -- (MARKET WIRE) -- March 30, 2007 -- Affibody Holding AB, a biotech company that has developed a late-stage pipeline of oncology products for molecular imaging and targeted therapy, issues new shares amounting to SEK 200 million. Affibody's mission is to provide the medical community with previously not available information for timely cancer diagnosis and appropriate individualized treatment regimes.

Back to news